Andrew Ip

2 months ago | onclive.com | Andrew Ip

“For many of us in the community who are referring [patients to] or treating [patients] with CAR T-cell therapy, we're trying to give them the quickest option, even though we realize there might be some more risks of toxicity.

Aug 26, 2024 | dental-tribune.com | Andrew Ip

Dental technology has allowed us to create excellent provisional restorations, cost-effective dentures, same-day or even same-appointment night guards, and more! However, the beauty of 3D printing is that applications are only limited by your imagination, restrictions in design software and the materials currently available on the market. It gives the clinician and technician the opportunity to let their creativity run rampant, all while improving the patient experience.

Jul 19, 2024 | digitalcommons.library.tmc.edu | Andrew Ip |Alex Mutebi |Tongsheng Wang |Monika Jun

INTRODUCTION: Despite new therapies for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatments with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents continue to be commonly used. METHODS: This retrospective study utilized longitudinal data from 4226 real-world electronic health records to characterize outcomes in patients with R/R DLBCL.

Jun 24, 2024 | onclive.com | Andrew Ip

Andrew Ip, MD, director, Hematologic Malignancies, John Theurer Cancer Center, discusses findings with alternative splicing of the TNFRSF17 gene, which encodes BCMA. Ip and colleagues conducted a study to explore the potential of the presence of alternative splicing in BCMA transcripts through the sequencing of BCMA RNA in patients with lymphoma or multiple myeloma. BCMA is a critical target for a variety of therapies, including CAR T cells, bispecific antibodies, and antibody-drug conjugates.

Apr 4, 2024 | onclive.com | Andrew Ip

Andrew Ip, MD, medical oncologist, John Theurer Cancer Center, Hackensack University Medical Center, discusses findings from a study assessing the feasibility of replacing flow cytometry analysis with next-generation sequencing (NGS) alongside machine learning to detect and diagnose hematologic malignancies, highlighting the clinical implications of this research.